Bacteria or "superbuki", adapted to counter multiple antibiotics, are responsible for 700 000 deaths in the world per year.

Researchers at Monash University in the framework of international cooperation identified a key part of the process by which a common clinical antibiotic. Their results were published in Chemical Science last week.

Scientists, led by the associate professor of the Monas Biology Institute (BDI) Max Krill and Dr.

Evie Stegmann of the University of Tubingen, investigated the so-called glycopeptide antibiotics, including vancomycin, a drug used as the last agent for the treatment of dangerous Staphylococcus aureus or "Golden Staph".

Researchers have identified a point on the assembly line on which a process occurs, called halogenation. It, in this case including the chlorine atom, plays a significant role in the activity of glycopeptide antibiotics. Knowing when and where it happens means that scientists can manipulate this part of the process and the end product of an antibiotic.

aspekty. net.